Dr. Matteo Samuele Pizzuto obtained his Master Degree in Industrial Biotechnology at the University of Padua and his PhD in Virology and Oncolytic Virotherapy at the Imperial College London.
He has been working in Ilaria Capua’s group at the FAO reference laboratory for avian influenza virus and has completed his training in reverse genetics at the Centre for Disease Control and Prevention in Atlanta (USA).
In 2017 he joined Humabs Biomed where he has been working as PI in a project sponsored by the Bill and Melinda Gates Foundation focused on the development of orally deliverable secretory IgA for immunoprophylaxis of campylobacter infections.
Humabs was acquired by Vir Biotechnology to become its subsidiary in Bellinzona, Switzerland.
Dr. Pizzuto is now Senior Scientist at VIR.